A systematic review by Dulai et al. reported an absolute rate of serious infections of 352 per 10,000 person-years in pediatric IBD patients receiving anti-TNF therapy, comparable to rates observed with IMM alone [53]. Here, TNF is linked to inflammatory bowel disease.